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The insulin-like growth factor (IGF) is a complex system of peptide hormones (insulin-like growth
factors of type 1 and 2, IGF-1 and IGF-2), cell surface receptors (insulin receptor, IR; insulin-like
growth factor receptors of type 1 and 2, IGF-R1, IGF-R2) and circulating binding proteins
(insulinlike growth factor binding proteins, IGF-BP 1-6). IGF-1 and -2 are mitogens that play a
role in regulating cell proliferation, differentiation and apoptosis. Their effects are mediated
through the IGF-R1 which initiates signaling cascades that result in regulation of a number of
biological responses. IGF-R2, together with IGF-BPs is involved in binding, internalization and
degradation of IGF-2. IGF proteins regulate cell proliferation in an interconnected action via
autocrine, paracrine and endocrine regulatory mechanisms. Consequently, any perturbation in
each level of the IGF signaling proteins has been shown to be implicated in development and
progression of numerous cancer types. The most important single components in this processes
are IGF ligands as well as IGF-R1 - when disturbed they act as oncogenes. It has been shown
that: (i) high serum concentrations of IGF-1 and IGF-2 are associated with an increased risk of
breast, prostate, colorectal and lung cancers; and (ii) IGF-R1 is commonly disturbed in many tumours
(like gastric, lung, endometrial cancer) leading to a phenotype of anchorage-independent tumour
growth. In contrast, IGF-R2 is considered to act as a tumour suppressor gene; it protects the cells
from neoplastic impulses. Consistent with the IGFs autocrine/paracrine regulation of tumour growth,
cancer treatment strategies interfering with IGF-R1 signaling have been developed, that may be
useful in future diagnostic and therapeutic strategies.
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Three critical early findings have been substantial
for subsequent research on IGF 1/2 signaling. First,
in 1957. Salmon et al found a growth hormone
dependent serum factor that stimulated35 S-sulphate
incorporation into rat cartilage1. It was designated as
«sulphation factor activity» (subsequently also termed
somatomedin C). Second, in early 1970s, a polypeptide
fraction with mitogenic activity was described in rat
liver conditioned medium. It was designated as
multiplication stimulating activity, MSA2. Third, several
laboratories identified serum components with
insulin-like activities which were not neutralized by
anti-insulin antibodies, so called non suppressible insulin-
like activity, NSILA3. Based on amino acid sequencing
analyses of these factors it was shown that all three
activities could be ascribed to two different peptides.
Because of their structural and functional homology
with insulin all former names are now replaced by the
term insulin-like growth factors, more precisely, insulin-
like growth factor 1 (IGF-1) and insulin-like growth
factor 2 (IGF-2).
Insulin, insulin-like growth factors, as well as later
discovered insulin-like growth factor receptors
Fig. 1. Schematic illustration of insulin, IGF-1 and IGF-2 molecules processing. Insulin is a small protein derived from prepro-insulin
(110 AA), by proteolitic cleavage of the signal peptide, formation of three disulphide bonds and cleavage of 35 AA C peptide. Active
form of insulin molecule is composed of two polypeptide chains, A (21 AA) and B (30 AA), joined by two disulphide bonds. Both
IGFs are highly homologous small single chain peptides derived from prepro-IGF-1 (130 AA) and prepro-IGF-2 (180 AA), respectively.
IGF-1 is 70 AA molecule organized into four peptide domains: A (21 AA), B (29 AA), C (12 AA) and D (8 AA). Domains A and B
are similar in structure to the insulin compartments (50% sesquence homology). The 12 AA C domains are similar in structure to the
C-peptide of pro-insulin. The both, IGF-1 and IGF-2 C-terminal E peptides are cleaved before secretion. IGF-2 (67 AA), like IGF-1,
is a single polypeptide composed of A and B domains, homologues with insulin and   IGF-1, and D (12AA) domains.
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(IGF R of type 1 and type 2) and insulin-like growth
factor binding proteins (IGF-BP 1-6) (IFG family of
peptides), play an important role in the normal control
of many metabolic and growth related processes. They
have been shown to have mitogenic and distinct
apoptotic effects regulating thereby the growth of
mammalian organism; they can act in endocrine (like
a hormone), and autocrine/paracrine manner.
Insulin-like growth factors
Both IGFs have been isolated and characterized
in the year 19704. They are highly homologous small
single chain peptides of 70 (IGF-1) and 67 (IGF-2)
amino acids respectively, and approximate 7.5 kD
size. The protein molecules of IGF-1 and IGF-2 can
be divided to B- (receptor binding domain), C-
(determines preferential binding to IGF-R1), A- (in
part, receptor binding domain), D- (determines the
affinity of IGF-2, but not IGF-1, to receptor binding)
and E-domains (Fig. 1). The proteins are 70 per cent
identical to one another, and 50 per cent to proinsulin,
mostly due to their B (residues 3-29 in IGF-1 and
residues 3-32 in IGF-2) domain. The C domains are
analogous in location to the C-domain of proinsulin,
but are not spliced out from the mature molecule, as
it happens during proinsulin processing. There is no
C-domain sequence homology either with each other
or with proinsulin. Then follows the A-domain, which
is homologous to the A-chain of insulin. Short C-
terminal D-domain, although homologous to each other,
is not found in insulin. The mature IGF-1 and IGF-2
do not possess the most C-terminal E-domain which
is cleaved from the promolecules post-translationally5.
The gene for IGF-1 is located on chromosome
12q22-q24.1. The gene for IGF-2 is located close to
the insulin one, on a chromosome 11p15.56.
IGF-1 is a trophic factor that circulates at high
levels in the blood stream. Although the main source
of IGF-1 in the serum is liver, many other tissues
synthesize it and are sensitive to its action, especially
during postnatal development7. Regulation of hepatic
IGF-1 production is mostly mediated by growth
hormone and insulin (Fig. 2). In turn, IGF-1 feeds
back to suppress growth hormone and insulin release.
In addition to growth hormone, developmental factors
as well as nutrition status all modify IGF-1
production7.
Fig. 2. Interactions between growth hormone (GH), insulin-like
growth factor I (IGF-I) and insulin-like growth factor binding
proteins (IGF-BPs). Arrows indicate activity while thin black
lines indicate inhibition. Growth hormone (GH) binds to GH
receptor (GH-R) which leads to IGF-1 production. IGF-1 binds
to IGF-R1 and causes enhanced growth and cell proliferation, as
well as anti-apoptotic and other effects. Interactions of IGF-BPs
with IGF-1 reduce the affinity of IGF-1 for IGF-R1. On the other
hand, associations of IGF-BPs with ECM decrease the affinity
of IGFBPs for IGFs and therefore increasing the level of free
IGFs. In addition, proteases cleave IGF-BPs rendering IGF-BPs
in fragments which have low affinity for IGFs. IGF-1, insulin-
like growth factor 1; IGF-R1, insulin-like growth factor 1 receptor;
IGF-BP-3, insulin-like growth factor binding protein 3; IGF-BP-
1, insulin-like growth factor binding protein 1; IGF-BP-2, insulin-
like growth factor binding protein 2; GH, growth hormone; GH-
R, growth hormone receptor; ECM, extracellular matrix.
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The synthesis of IGF-2 is relatively growth
hormone independent. Its expression is much higher
during foetal development than in postnatal life. It acts
as a regulatory peptide; it is mitogenic for a number
of cell types. The IGF-2 gene is transcribed from four
different promoters (P1-P4). P2-P4 contains CpG
islands, and transcription from these promoters is
subject to imprinting. Monoallelic expression from
these promoters occurs mostly in foetal and young
tissues. The P1 promoter, utilized primarily in adult
liver tissue, is regulated differentially; it escapes
imprinting and is expressed biallelically8. The IGF-2
gene can be expressed to produce proteins of various
molecular weights. The most active form, with regard
to binding to IGF receptors, is 7.5 kDa9. Larger forms
lack post-transcriptional cleavage and have been
implicated in hypoglycaemia, which can accompany
a variety of tumours.
Insulin-like growth factor receptors
The biological effects of IGF-1 and IGF-2 on a
target cell are mediated by two types of cell surface
receptors: IGF receptor of type 1 (IGF-R1) and IGF
receptor of type 2 (IGF-R2), as well as through binding
to receptors for insulin (Fig. 3). IGF-1 binds to the
type 1 receptor, and with a lower affinity to insulin
receptor. IGF-2 binds with high affinity to the type
2 receptor and with low affinity to the type 1
receptor. It has no affinity for the insulin receptor.
The type 2 receptor is identical to the cation-
independent mannose-6- phosphate receptor. In
general, most of the action of IGFs is mediated via
IGF-R17. As well as insulin receptor, it is a member
of tyrosine-kinase class of growth factor receptors.
It is a heterotetramer, consisting of two α- (ligand
binding) subunits, and two transmembrane β-subunits
which contain a tyrosine kinase domain, that activates
receptor by autophosphorylation. Binding of ligand
(IGF-1 and GF-2) to the extracellular part of IGF-
R1 initiates a cytoplasmic signal cascade that includes
receptor conformational change which enables them
to bind ATP and become autophosphorylated on
tyrosine residues within the β-subunits, resulting in
activation of the intrinsic tyrosine kinase activity of
the IGF-R1 and subsequent tyrosine phosphorylation
of several substrates, including IRS and Shc. This
stimulates downstream signaling through intracellular
networks that regulate cell proliferation and survival.
Key downstream molecules include the phosphatidyl
inositol-3 kinase (PI3K)-serine/threonine protein
kinase B (PKB or AKT) - target of rapamycin (TOR)
system and serine/threonine kinase (RAF)-mitogen
activated protein kinase (MAPK) system. Activation
of these pathways results in variety of responses, such
as cell proliferation, differentiation, migration and
protection from apoptosis.
In addition to be stimulated by IGF-2, IGF-R1 is
overexpressed in some tumours. Overexpression of
these receptors, independent of exogenous peptides
transforms cells to a phenotype of anchorage-
independent growth10.
The type 2 IGF receptor, also known as cation-
independent mannose-6-phosphate receptor (IGF-R2/
M-6-P), is structurally and functionally different from
the IGF-R1. The receptor is monomeric membrane
spanning glycoprotein of 250 kDa, with a large
extracellular domain, which binds M-6-P, lysosomal
enzymes, and IGF-211. The extracellular part contains
one binding site for IGF-2 and two sites for M-6-P
containing ligands. This suggests that IGF-R2/M-6-
P may be involved in the clearance of IGF-2 from
the circulation (on the cell surface the IGF-R2 is
constitutively endocytosed, where its main role is the
binding and internalization of IGF-2) and in the
modulation of trafficking of lysosomal enzymes.
IGFR2 does not have intracytoplasmatic signaling
domain and is thought to be recycled between the
plasma and different cellular compartments. The gene
for IGF-R2 is located on chromosome 6q. In opposite
to the gene for IGF-2 it is paternally imprinted (Fig. 3).
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IGF binding proteins and proteases
The IGF binding proteins represent a family of
six conserved proteins (IGF-BP 1-6) with the
common property of binding IGF-1 and IGF-2
present in serum and other biological fluids12
(Table; Fig. 4). The genes for human IGF-BP are
located on different chromosomes: genes for
IGF-BPs 1 and 3 on chromosome 7, genes
for IGF-BPs 2 and 5 on chromosome 2, the gene
for IGF-BP 4 on chromosome 17 and the gene for
IGF-BP 6 on chromosome 613. IGF binding to IGF-
BP may be modulated by IGF-BP modifications,
such as glycosylation, phosphorylation and
proteolysis, and by IGF-BP association with
cell surface or components of the extracellular
matrix. All IGF-BPs inhibit IGF action by
sequestering IGFs, and prolong their half-life
Table. Some structural and functional properties of insulin-like growth factor binding proteins (IGF-BP 1-6)
IGF-BP-1 IGF-BP-2 IGF-BP-3 IGF-BP-4 IGF-BP-5 IGF-BP-6
Gene location 7p14-p12 2q33-q34 7p14-p12 17q12-q21 2q33-q36 12b
(chromosome)a
Amino acids 234 289 264 237 252 216
Cysteine rich + + + + + +
N-region
Cysteine rich + + + + + +
C-region
Central L + + + + + +
domain
Glycosilation – – N-linked N-linked O-linked O-linked
nonglycosilated
Phosphorylation + – + – + NDc
Proteolysis + serine proteased PAPP-Ae, MMPsf, calcium dependent serine proteased trypsin
(protease) PSAg, cathepsin-D serine protease MMPs chymotrypsin
Synthesized by liver, maternal hepatocytes, liver, specific subset mesenchimal/ mesenchimal cells developmentaly
placenta epithelial cells of mesenchimal cells epithelial cells connective tissue regulated
Expressed in amniotic fluid serum serum all biological fluids serum physiological
fluids
Binding to cell surface cell surface cell surface proteins soluble cell surface, limited cell
(RGD)h (RGD)h, ECMi (receptors?) ECM extracellular form ECM surface
Proposed action inhibit, inhibit, inhibit, potentiate, inhibit inhibit potentiate, inhibit
potentiate potentiate IGF independent IGF independent (?) IGF independent
Affinity for IGF-1- IGF-1 (lower) IGF-1 (very high) IGF-1 and -2 with IGF-1 IGF-2
phosphorylation IGF-2 (higher) similar affinities (very high) (very high)
dependent
aall genes are structurally similar; possess 4 conserved exons; bexact position not known; cnot determined; dND, exact identity not
established; ePAPP-A, pregnancy associated plasma protein (cation dependent serine protease); fMMPs, matrix metalloproteases1
and 2; gPSA, prostate specific antigen; hRGD motif, Arg-Gly-Asp - integrin-binding motif; iECM, extracellular matrix
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in the plasma, whereas some of them, like IGF-BP 1,
-3 and -5 also potentiate IGFs action. In addition, IGF-
BP 3 and -5 also have IGFs independent action, via
signaling through BPs cell surface receptors. (Fig. 4).
Proteins that bind IGF-BPs can be classified into
three families. The first includes components of the
extracellular matrix where binding of the IGF-BPs
regulates IGF bioavailability. The second includes
transmembrane proteins that are plasma membrane
components and can induce intracellular signals (L5β1
integrin, type V transforming growth factor TGFβ
receptor) while the third includes intracellular proteins
localized in nucleus or cytosol (retinoid X receptor-
α, retinoic acid receptor-α, importin-β, Four-and-a-
half LIM protein 2)14.
IGF-BP degrading proteases act as growth
stimulators by increasing local IGF availability. They
fall into three major categories15. Kallikrein-like serine
proteases, which cleave IGF-BP 3, include prostate
specific antigen (PSA), gamma nerve growth factor
and plasmin. Thrombin, another serine protease,
cleaves IGF-BP 5. The second major category is
cathepsins, intracellularproteinases, and the third
category involves matrix metalloproteinases, a family
of peptide hydrolases that function in tissue
remodeling by degradation of extracellular matrix
components. Proteolytic activity by proteases may
play a role in normal and abnormal tissue proliferation
by cleaving IGF-BP into fragments with lower affinity
for IGFs, thereby increasing the levels of free IGFs
to activate IGF-R1.
IGFs and cancer
During the past two decades, the joint efforts of
several laboratories have firmly established the
important role of IGF family of peptides (ligands,
receptors, binding proteins and proteases) as mitogens
for variety of tumour types. As their action is strongly
interrelated, any deregulation of interactions among
them may lead to the pathological condition, mostly
cancer formation and progression. In this respect, very
often, IGF-1 and IGF-2 overproduced by tumour cells
act as autocrine stimulators of malignant cells division,
through binding and stimulating the activity of IGF-
R1. These have been shown first in vitro16,17, and
later on in vivo18-21 as well as in clinical studies22.
Based on a cell culture experiments conducted on
prostate, breast, lung, colon, stomach, endometrial,
liver, brain, and many other cell lines it was presumed
that growth hormone-IGF-1 axis plays a role in
neoplastic pathology16,17. In vivo, for instance, it was
possible to induce tumour growth by the molecules
isolated from the tumour stromal cells or tumour host
serum18-21. Moreover, tumour cells with nonfunctional
IGF receptors could induce their own proliferation by
the synthesis of endogenous IGF molecules. This
process of autocrine stimulation contributed in part
to the autonomous and faster tumour growth22.
More than 20 yr ago we have also described the
involvement of IGF in cancer18,21. Increased glucose
level in the blood of diabetic but normoinsulinaemic
mice was accompanied by suppressed growth of
mammary carcinoma23. The same tumours, as well
as some other murine tumour cell types maintained
in hypoinsulinaemic mice grew faster after each
subsequent transplantation into diabetic mice. The
observed proliferation enhancement of tumours was
caused by de novo synthesis of insulin-like protein,
by the tumour cells themselves18-20. Later we showed
that IGFs appear in many experimental and human
tumours21,24-27. As it was shown for human
hemangiopericytomas, increase in tumour size was
paralleled by an elevation of IGFs in the serum.
Removal of tumours (from the patients) eliminated
most of the IGF-2 serum activity. Moreover, when
IGF-2 was added to the cell cultures of
hemangiopericytomas, cell proliferation was
significantly increased. It appeared that IGF-2
produced by tumour cells stimulated tumour cell
proliferation by autocrine mechanism21,24.
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Maybe the most important proof for the
involvement of IGFs to tumour growth and progression
comes from the clinical studies. For instance, several
studies have shown the link between serum
concentration of (i) IGF-1 and IGF-BP 3 with
increased risk of breast, prostate, colorectal and lung
cancer28; (ii) IGF-2 with increased risk of colorectal
cancer29. Overexpression of IGF-2, as measured at
Fig. 3. Overview of insulin receptor (IR), insulin-like growth factor 1 receptor (IGF-R1) and insulin-like growth factor 2 receptor
(IGF-R2) activation and downstream signaling. The thickness of arows indicates the affinity of the ligands for the receptors. Following
ligand binding to insulin receptor metabolic pathways are activated. After ligand binding to IGF-R1, its tyrosine kinase activity is
activated, which stimulates signaling involved in regulation of cell proliferation and cell survival. Activating key pathways PI3K-
AKT-TOR and RAF-MAPK systems, results in stimulation of proliferation and inhibition of apoptosis. Upon ligand binding to
IGF-R2, the receptor is internalized and degraded. IGF-BPs are competitive inhibitors of the IGFs; IGF-BP-3, as well as some other
BPs like BP-1 and BP-2, binds to IGF-1 while IGF-BP-6 binds to IGF-2. IGF-1, insulin-like growth factor 1; IGF-2, insulin-like
growth factor 2; IGF-R1, insulin-like growth factor 1 receptor; IGF-R2, insulin-like growth factor 2 receptor; IGF-BP-3, insulin-like
growth factor binding protein 3; IGF BP-6, insulin-like growth factor binding protein 6; PI3K, phosphatidylinositol 3-kinase; TOR,
target of rapamycin; MAPK, mitogen-activated protein kinase.
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the level of mRNA and protein, is also found in variety
of cancers, including lung, gastric cancer and
hemangiopericytomas21,25-27.
However, it seems today that the predominating
single factor among IGFs implicated in cancer, is
IGF-R1 whose overexpression (therefore augmented
signaling) could promote tumour formation and
maintenance even at the normal levels of IGF-1 and
IGF-2, by an autocrine mechanism. It has also been
shown to be crucial for anchorage-independent growth,
the property unique to tumour cells. Several studies,
both experimental and clinical, have demonstrated that
the IGF-R1 is overexpressed in tumour cells30
contributing to tumour formation, maintenance and
progression. The results of our studies also indicate the
importance of IGF-R1, together with IGF1 and IGF-2,
in pathogenesis of lung  cancer, hemangiopericytomas,
and gastric cancer. For instance, 12 of 22 tested human
hemangiopericytomas overexpressed IGF-2, and even
Fig. 4. Structure of IGF-BP 1-6. IGF-BPs are approximately 30 kDa proteins that share a common domain organization consisting of
cysteine-rich N and C terminal domains connected by a flexibile linker region (L). IGF binding sites are located on both the N and C
domains. The only identified function of N-domains of IGF-BPs is IGF binding, but C-domains are implicated in wide range of
function by interacting with numerous molecules that can modulate IGF-dependent or IGF-independent action. The L domains of
IGF-BPs 1-6 are not conserved and are not directly involved in high-affinity IGF binding. The L domains are also sites of post-
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90 per cent of them IGF-R1, as recorded at the level
of mRNA21. Similarly, we have also shown that
majority of human lung cancers tested (all together
69) overexpress simultaneously IGF-1, IGF-2, IGF-
R1 and IGF-BP 4. Seventeen tumours were
concomitantly positive for all four IGFs, whereas 34
were positive for IGF-2, IGF-R1 and IGF-BP 4. At
the same time, these tumours were negative for IGF-
R225. IGF-2 is also secreted by human gastric cancer
cells, of both, diffuse and intestinal type, as we have
shown by culturing these tumours in vitro26. At the
same time the mRNA for IGF-2 and IGF-R1 was also
overexpressed in both gastric cancer types. In
contrast, the synthesis of IGFR-2 was diminished in
these cancers.
Regarding to the role of IGF-R2 in cancer
formation, it should be emphasized that this receptor
has no intrinsic signaling transduction capability and
in the context of the IGF system primarily acts to
sequester IGF-2 from the circulation. Mutation or loss
of expression, resulting in loss of heterozygosity, of
the IGF-R2 gene occurs in several cancers and
correlates with a poor prognosis, indicating this gene
as a tumour suppressor31,32. We have shown, in
human lung cancers, that IGF-R2 gene deregulation
is connected to the mutations in this tumour
suppressor26. The mutations were connected with
more aggressive tumour types, high proliferation index,
as well as autocrine overproduction of IGF-2.
As the defects in IGFs that are commonly seen
in cancers are mostly associated with overexpression
of IGF-1/IGF-2 and/or IGF-R1 as well as mutations
in the IGF-R2 gene, targeting at the level of these
four molecules would be a reasonable choice for the
treatment of IGF-dependent cancers.
Targeting growth factors and their receptors
In principle, autocrine circuits of IGFs can be
interrupted at two points: outside and inside the cell.
The most widely investigated outside approach is the
use of blocking antibodies directed against the
extracellular part of the receptor33,34. However,
laboratory studies are also directed to the use of
inhibitors of ligand binding, and the use of competitive
binding antagonists35,36. Inside the cell antisense
strategies and the use of small interfering RNA
(siRNA) are the tools of choice to reduce receptor
expression. There is also a great interest in
therapeutic strategies that target signaling downstream
of IGF-R135,36.
There are only a few studies that describe
targeting of IGF-2 production as cancer therapy
strategy. For instance, it was shown that an analogue
of gonadotropin-releasing hormone (GnRH),
tryptorelin, exerts a biphasic growth effect on ovarian
cancer cells (that express GnRH binding sites), by a
mechanism of diminished autocrine production of
IGF-237. Similarly, the GnRH antagonist, SB-75,
inhibited growth of gynaecological cancer cells, again
by inhibition of IGF-2 secretion38-40.
Reduction of IGF-1 levels by the use of somatostatin
analogues, GHRH or GH antagonists41-43 have shown,
so far, only a modest success. However, Csernus et
al44 suggested that antagonistic analogues of GHRH
can inhibit the growth of certain tumours not only by
inhibiting the GHRH-GH-IGF-2 axis, but also by
reducing IGF-2 production and by interfering with the
autocrine regulatory pathway. Antagonists of GHRH
directly block the expression of IGF-2 mRNA and, as
a consequence, the production of IGF-2. GHRH
significantly inhibits the rate of proliferation of
mammary, prostatic, and pancreatic cancer cell lines.
Blocking of IGF-R1 seems to be promising approach
for the development of an IGF-2 dependent cancer
therapy. Receptor function can be abrogated by
utilizing monoclonal antibodies against receptors such
as αIR326, use of polyanionic compound suramine45,
or exploiting antisense oligodeoxynucleotides directed
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against the IGF-R1 mRNA. The αIR3 monoclonal
antibody recognizes human IGF-R1 and neutralizes
IGF-1 and IGF-2 mediated signal transduction
pathway. Its blocking effects on IGF-1 and IGF-2
mediated responses have been shown in vitro and in
vivo25,46-48. This approach was also tested and
supported with results of our previous experiments
conducted on malignant hemangiopericytomas21,24.
According to Arteaga49, blockade of the IGF-R1
may be even more effective when used in conjunction
with other manipulations that also target the IGF system.
This approach was supported by the results obtained
in our previous experiments21. IGF-BP and somatostatin
analogues are also potentially rational candidates for
combined therapy with monoclonal antibodies or
antisense oligonucleotides against IGFR1/ IGF-250.
Conclusions
Since IGF proteins are involved in cell proliferation
regulation, any disturbance of the IGF signaling
proteins has been shown to be connected with
development and progression of many cancer types.
Considering that high serum concentrations of
IGF-1 and IGF-2 are associated with an increased
risk of breast, prostate, colorectal and lung cancers
and that IGF-R1 is commonly overexpressed in many
tumours (like gastric, lung, endometrial cancer) leading
to a phenotype of anchorage-independent tumour
growth, it is reasonable that interfering with IGF-R1
signaling approach is considered as one of the
promising cancer treatment strategies.
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